BD's own tests showed Alaris infusion sets perform worse than disclosed — Class I recall

On August 19, 2026 BD initiated recall Z-3080-2026, and on October 5 the FDA expanded its public communication: updated testing showed some BD Alaris Pump Infusion Sets used with the Model 8100 pump module perform substantially worse than previously disclosed, most commonly at programmed rates below 1 mL/h and bolus volumes of 5 mL or less. The affected system includes BD Alaris with Guardrails Suite MX software up to v12.6. The recall is classified Class I, and FDA links it to three earlier actions: Z-0035-2026, Z-2180-2025 and Z-2179-2025.

The performance deviations matter because set components — closed male luers, filters, check valves, Y-sites, microbore tubing — change how the pump delivers, and at low rates and small boluses, the range used for neonates, pediatric and critically ill patients on drugs like antiarrhythmics and blood-pressure support, the result can be greater under- or over-infusion, delayed occlusion alarms and inaccurate boluses that are hard for clinicians to recognise. FDA states these could cause serious adverse events or death; BD reported no serious injuries or deaths as of August 19, 2026.

BD's customer instructions tell hospitals to immediately identify and discard the infusion sets listed as discontinued, select alternative Alaris sets, prioritise limited alternative supplies for critical-care and neonatal areas, and adjust clinical use against updated performance disclosures — or fall back on syringe pumps and enhanced monitoring where none are available. It is the third Alaris disclosure failure on BD's record since 2016, after the $175M SEC penalty for hiding pump risks to protect guidance and the concealed $59M in recall costs that overstated 2019 profit.

Class I recall Z-3080-2026, fourth linked action since 2025; hospitals scrapping discontinued sets and rationing scarce alternatives; no injuries reported

BD disclosed performance data for the sets that its own updated testing proved optimistic, in exactly the low-flow, low-volume range where infusion errors are hardest to detect.

The fix requires hospitals to re-sort their set inventories and ration scarce alternatives for the most vulnerable patients, a burden the disclosure error pushed onto customers.

The company had already been penalised twice for Alaris-related disclosure failures, making the third instance a pattern rather than a one-off lapse.

For a device whose failures are invisible at the bedside, published performance data is the product: publish the ugly curves first, not after the FDA asks.

The recall is open and classified, with BD Switzerland Sarl the recalling firm for Z-3080-2026 and CareFusion 303 for the linked earlier actions; FDA's affected-product spreadsheet distinguishes discontinued sets from sets still available with revised performance disclosures. No injuries or deaths had been reported by August 2026, and no penalty appears in the material.